Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05142592 · ClinicalTrials.gov registry record · Phase 1
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
A Phase 1 study of Pharmacokinetics and Safety Issues, sponsored by Nanjing Immunophage Biotech Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 196
- Enrollment target
- 7
- Study locations
NCT05142592: Recruiting Phase 1 study of Pharmacokinetics and Safety Issues, sponsored by Nanjing Immunophage Biotech Co..
NCT05142592 is a Phase 1 study of Pharmacokinetics and Safety Issues that is actively recruiting participants, run by Nanjing Immunophage Biotech Co.. The registered enrollment target is 196 participants, above the 57-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (244% higher). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05142592, a Phase 1 study of Pharmacokinetics and Safety Issues, is actively recruiting participants, sponsored by Nanjing Immunophage Biotech Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 196 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and preliminary anti-tumor activity of IPG7236 administered orally as a single agent to patients with advanced solid tumors. The study will include a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2a). Each part will consist of a screening period of up to 28 days, a treatment period, an end of treatment visit and a safety follow-up of approximately 30 days after the last dose. IPG7236 will be given on an empty stomach (either one hour before or two hours after a meal) twice daily (approximately every 12±1 hours) in continuous 28-day cycles.
Primary Outcome
Evaluation of adverse events
Conditions Studied
Interventions
- DRUG IPG7236
Study Locations (7)
Other
- Shanghai East Hospital - Shanghai
- Shanghai General Hospital - Shanghai
- Shanghai GoBroad Cancer Hospital China Pharmaceutical University - Shanghai
Oregon
- Providence Portland Medical Center - Portland
Texas
- NEXT Oncology - Austin
Jiangxi
- The First Affiliated Hospital Nanchang Univeristy - Nanchang
Shangdong
- Shandong Cancer Hospital - Jinan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2025-12-21 |
| Phase | Phase 1 |
What NCT05142592 shows while recruiting
NCT05142592 is an interventional study that assigns participants to a tested intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, above the 57-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (244% higher).
The record links to 3 conditions, with Pharmacokinetics appearing as the primary indexed condition, and to 1 intervention - of which IPG7236 is the first listed.
NCT05142592 lists 7 locations in 5 states (Other, Oregon, Texas).
Frequently Asked Questions
What is clinical trial NCT05142592 about?
NCT05142592 is a clinical study titled "Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors". This is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and preliminary anti-tumor activity of IPG7236 administered orally as a single agent to patients with advanced solid tumors. The study will include a dos...
What is the current status of trial NCT05142592?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 196 participants. The study started on 2021-11-15. Estimated completion is 2025-12-21.
What conditions does trial NCT05142592 study?
This clinical trial studies the following conditions: Pharmacokinetics, Safety Issues, Tolerability.
What interventions are being tested in trial NCT05142592?
The interventions under investigation include: IPG7236 (DRUG).
Who is sponsoring clinical trial NCT05142592?
This trial is sponsored by Nanjing Immunophage Biotech Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05142592 being conducted?
This trial has 7 study locations across Oregon, Texas, Jiangxi, Shangdong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05142592's enrollment target sits among peer trials
196 3rd of 37 higher than 35 of 37 other Pharmacokinetics trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pharmacokinetics trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
ACTIVE NOT RECRUITING · Phase 1
-
Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02822768 · 196 participants · NA
Packing Versus no Packing for Cutaneous Abscess
- NCT04250259 · 196 participants · Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
- NCT05317832 · 196 participants · Phase 2
Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
- NCT05736666 · 196 participants · NA
Treadmill Perturbation Training for Fall Prevention After Total Knee Replacement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI